Loading...
IFRX logo

InflaRx N.V.NasdaqGS:IFRX Stock Report

Market Cap US$371.2m
Share Price
US$2.38
US$7.4
67.8% undervalued intrinsic discount
1Y33.7%
7D-10.2%
Portfolio Value
​
View

InflaRx N.V.

NasdaqGS:IFRX Stock Report

Market Cap: US$371.2m

InflaRx (IFRX) Stock Overview

A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details

IFRX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 77.67% per year

Risk Analysis

Makes less than USD$1m in revenue (€29K)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 16.6% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

IFRX Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

InflaRx N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for InflaRx
Historical stock prices
Current Share PriceUS$2.38
52 Week HighUS$2.95
52 Week LowUS$0.71
Beta2.44
1 Month Change108.77%
3 Month Change176.81%
1 Year Change33.71%
3 Year Change-45.54%
5 Year Change-18.77%
Change since IPO-84.12%

Recent News & Updates

Recent updates

Analysis Article • Feb 06

Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Nov 20

InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)

Summary InflaRx faces worsening prospects as Gohibic remains niche, unprofitable, and unlikely to drive meaningful revenue growth. Attempts to expand vilobelimab into new indications failed, prompting a strategic pivot to the early-stage asset INF904. Early INF904 data in HS and CSU are underwhelming, with class safety concerns and past failures weighing on IFRX's outlook. With dwindling cash reserves and a high burn rate, IFRX is rated a clear 'Sell' due to excessive risks and uncertain turnaround. Read the full article on Seeking Alpha
Analysis Article • Jul 10

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 25

InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 23

We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 17

InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 28

We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 30

Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 29

InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients

German clinical-stage biopharma InflaRx (NASDAQ:IFRX) on Thursday said it had submitted an emergency use approval request to the U.S. FDA for its monoclonal antibody vilobelimab to treat critically ill COVID-19 patients. The company also said it was granted a fast track designation from the U.S. drug regulator for vilobelimab. IFRX stock +5.6% to $2.63 in early trading. The submission for the emergency use nod and the fast track clearance was based on the results of phase 3 studies conducted in invasively mechanically ventilated, critically ill COVID patients, IFRX said in a statement. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The submission from InflaRx (IFRX) comes at a time when COVID cases in the U.S. are expected to rise in the fall and winter season.
Seeking Alpha • Aug 05

InflaRx reports Q2 results

InflaRx press release (NASDAQ:IFRX): Q2 GAAP EPS of €0.01. On June 30, 2022, the Company’s total funds available were approximately €91.8 million, composed of cash and cash equivalents of €15.4 million and marketable securities of €76.4 million. These funds are expected to finance operations until year-end 2024.
Seeking Alpha • Jul 26

InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients

InflaRx (NASDAQ:IFRX) stock rose ~13% on July 26 after its CEO Niels Riedemann said the company plans to submit a request for an emergency use authorization (EUA) of its COVID-19 drug vilobelimab in the U.S. by the end of Q3. The Germany company said it had encouraging interactions with the U.S. Food and Drug Administration (FDA) at a recent Type B meeting which was held to discuss a potential EUA filing and the development of monoclonal antibody vilobelimab for critically ill invasively mechanically ventilated patients with COVID-19. InflaRx noted that it discussed in detail a completed phase 3 part of the PANAMO study in invasively mechanically ventilated, critically ill patients with COVID-19. In March, the company reported data from the phase 3 trial in which vilobelimab did not show statistical significance in reducing risk of death in mechanically ventilated patients with COVID-19. "Our constructive interactions with the FDA and the helpful guidance they provided have encouraged us to move forward with applying for EUA for vilobelimab in critically ill COVID-19 patients," said InflaRx Founder and CEO Riedemann.
Analysis Article • Jul 16

Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jul 06

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG). PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs. The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release. Vilobelimab has already received orphan drug status for PG in the U.S. and EU. IFRX +14.08% to $1.62 premarket July 6
Seeking Alpha • Jun 29

InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy

German biotech InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday that the FDA agreed to a Type B meeting as the company seeks emergency use authorization for its COVID-19 therapy, vilobelimab  InflaRx (IFRX) has engaged the agency to discuss the future regulatory path for vilobelimab in COVID-19 after its multi-national PANAMO study for patients with the severe form of the disease generated favorable Phase 3 results early this year. The FDA has scheduled a Type B meeting for early Q3 to provide guidance on a potential emergency use authorization submission. Meanwhile, the discussions with the European Medicines Agency (EMA) are currently underway, targeting a regulatory submission for the same indication. Updating on the development of vilobelimab for the rare skin disorder pyoderma gangrenosum, InflaRx (IFRX) said that the company is now finalizing the design for a Phase III trial. That was after an end-of-phase II meeting, in which the FDA supported a randomized, controlled late-stage study and offered to review the study protocol. Read more on the topline data from the PANAMO study.
Analysis Article • Apr 01

Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Dec 29

Our First Look At InflaRx

Today, we shine the spotlight on InflaRx, a small biotech concern based in Germany. The stock is deep in 'Busted IPO' territory even as the company has seen an increasing amount of news flow around it in recent months. A full investment analysis follows in the paragraphs below.

Shareholder Returns

IFRXUS BiotechsUS Market
7D-10.2%1.0%1.1%
1Y33.7%40.3%26.7%

Return vs Industry: IFRX underperformed the US Biotechs industry which returned 44.4% over the past year.

Return vs Market: IFRX exceeded the US Market which returned 25.4% over the past year.

Price Volatility

Is IFRX's price volatile compared to industry and market?
IFRX volatility
IFRX Average Weekly Movement15.6%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: IFRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IFRX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200765Niels Riedemannwww.inflarx.de

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.

InflaRx N.V. Fundamentals Summary

How do InflaRx's earnings and revenue compare to its market cap?
IFRX fundamental statistics
Market capUS$371.18m
Earnings (TTM)-US$50.08m
Revenue (TTM)US$34.23k
Over9,999x
P/S Ratio
-7.0x
P/E Ratio

Is IFRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IFRX income statement (TTM)
Revenue€29.33k
Cost of Revenue€7.26m
Gross Profit-€7.23m
Other Expenses€35.68m
Earnings-€42.91m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.29
Gross Margin-24,646.27%
Net Profit Margin-146,303.92%
Debt/Equity Ratio0%

How did IFRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 15:12
End of Day Share Price 2026/05/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InflaRx N.V. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Mayur SomaiyaBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.